Thomas John Dietz, Director at Eiger BioPharmaceuticals, Inc. (EIGR), sold 22,500 shares at $1.17 ($26K) on 2022-12-22, disclosed to the SEC on 2022-12-27.
Open-market sale of $26k EIGR by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| EIGR | BUY | 2021-04-12 | $21K | — | Filing → |
| EIGR | BUY | 2020-03-17 | $5K | — | Filing → |
| EIGR | BUY | 2020-01-13 | $56K | — | Filing → |